Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: Follow-up care after treatment for prostate cancer: evaluation of a supported self-management and remote surveillance programme

 

All

Programme group

Comparator group

(n = 627)

(n = 293)

(n = 334)

Centre

 1

155 (25)

99 (34)

56 (17)

 2

202 (32)

100 (34)

102 (31)

 3

146 (23)

53 (18)

93 (28)

 4

124 (20)

41 (14)

83 (25)

Ethnicitya

 White

607 (97)

281 (97)

326 (99)

 Mixed

2 (0)

1 (0)

1 (0)

 Asian

4 (1)

3 (1)

1 (0)

 Black

4 (1)

4 (1)

0

 Other

4 (1)

2 (1)

2 (1)

 Missing

6 (1)

2 (1)

4 (1)

Qualificationsa

 No qualifications

166 (27)

70 (24)

96 (30)

 GCSE/O level

106 (17)

46 (16)

60 (18)

 Vocational

131 (21)

63 (22)

68 (21)

 A level

45 (7)

28 (10)

17 (5)

 Undergraduate

54 (9)

27 (9)

27 (8)

 Postgraduate

34 (6)

21 (7)

13 (4)

 Other

81 (13)

35 (12)

46 (14)

 Missing

10 (2)

3 (1)

7 (2)

Employment statusa

 Retired

479 (77)

224 (77)

255 (77)

 Employed full time

56 (9)

27 (9)

29 (9)

 Employed part time

34 (5)

18 (6)

16 (5)

 Employed on sick leave

5 (1)

1 (0)

4 (1)

 Self employed

33 (5)

16 (6)

17 (5)

 Disabled or long term sick

13 (2)

3 (1)

10 (3)

 Unemployed

3 (0)

2 (1)

1 (0)

 Missing

4 (1)

2 (1)

2 (1)

Marital statusa

 Married/civil partnership

507 (81)

233 (80)

274 (82)

 Widowed

36 (6)

19 (6)

17 (5)

 Living with partner

33 (5)

17 (6)

16 (5)

 Divorced/separated

31 (5)

15 (5)

16 (5)

 Single

19 (3)

9 (3)

10 (3)

 Missing

1 (0)

0

1 (0)

Living

 In own home

554 (88)

260 (89)

294 (88)

 In rented home

57 (9)

29 (10)

28 (8)

 Temporary accommodation

3 (1)

1 (0)

2 (1)

 Other

13 (2)

3 (1)

10 (3)

Caring responsibilities for children or adultsa

 Yes

75 (12)

41 (14)

34 (10)

 No

548 (88)

251 (86)

297 (90)

 Missing

4 (1)

1 (0)

3 (1)

Access to the internet at homea

 Yes

530 (85)

254 (87)

276 (83)

 No

96 (15)

39 (13)

57 (17)

 Missing

1 (0)

0

1 (0)

Index of Multiple Deprivation decilea

 1

25 (4)

13 (5)

12 (4)

 2

28 (5)

15 (5)

13 (4)

 3

51 (8)

21 (7)

30 (9)

 4

88 (14)

39 (14)

49 (15)

 5

89 (15)

36 (13)

53 (16)

 6

75 (12)

34 (12)

41 (13)

 7

64 (10)

34 (12)

30 (9)

 8

72 (12)

41 (14)

31 (9)

 9

70 (11)

29 (10)

41 (13)

 10

53 (9)

24 (8)

29 (9)

 Missing

12 (2)

7 (2)

5 (2)

Age of participant (in years)

 Mean (SD)

70 (7)

70 (7)

71 (7)

 Min to max

44 to 91

45 to 84

44 to 91

Time since diagnosis (in years)a

 Mean (SD)

2 (2)

2 (2)

2 (2)

 Min to max

0 to 14

0 to 14

0 to 14

n

623

292

331

Time from treatmenta

 0–1 years

314 (51)

160 (56)

154 (47)

 > 1–2 years

185 (30)

69 (24)

116 (35)

 > 2–3 years

114 (19)

56 (20)

58 (18)

 Missing

14 (2)

8 (3)

6 (2)

Number of comorbidities

 Mean (SD)

2 (1)

2 (1)

2 (1)

 Min to max

0 to 6

0 to 5

0 to 6

Treatmenta

 Radical prostatectomy

178 (29)

83 (29)

95 (29)

 External Beam Radiotherapy (EBRT)

54 (9)

23 (8)

31 (9)

 Hormone therapy (HT)

91 (15)

27 (9)

64 (19)

 Brachytherapy (BT)

4 (1)

2 (1)

2 (1)

 EBRT and HT

264 (43)

143 (50)

121 (37)

 BT and HT

14 (2)

9 (3)

5 (2)

 BT and EBRT

3 (1)

1 (0)

2 (1)

 BT and EBRT and HT

12 (2)

1 (0)

11 (3)

 Missing

7 (1)

4 (1)

3 (1)

T Stagea

 T1

64 (11)

32 (11)

32 (11)

 T2

255 (44)

119 (42)

136 (45)

 T3

237 (40)

118 (42)

119 (39)

 T4

24 (4)

12 (4)

12 (4)

 T stage unknown

4 (1)

1 (0)

3 (1)

 Missing

43 (7)

11 (4)

32 (10)

N Stagea

 N0

528 (91)

262 (91)

266 (92)

 N1

33 (6)

14 (5)

19 (7)

 N stage unknown

17 (3)

12 (4)

5 (2)

 Missing

49 (8)

5 (2)

44 (13)

M Stagea

 M0

551 (95)

273 (95)

278 (95)

 M1

19 (3)

7 (2)

12 (4)

 M stage unknown

12 (2)

8 (3)

4 (1)

 Missing

45 (7)

5 (2)

40 (12)

PSA at diagnosisa

 Less than 10

287 (48)

142 (49)

145 (46)

 10 to 20

163 (27)

83 (29)

80 (26)

 More than 20

154 (25)

65 (22)

89 (28)

 Missing

23 (4)

3 (1)

20 (6)

Risk stratification (3)

 Advanced (metastatic)

17 (3)

7 (2)

10 (3)

 Localised high risk

65 (10)

31 (11)

34 (10)

 Localised intermediate risk

183 (29)

96 (33)

87 (26)

 Localised low risk

36 (6)

15 (5)

21 (6)

 Localised risk unknown

8 (1)

3 (1)

5 (2)

 Locally advanced

245 (39)

123 (42)

122 (37)

 Insufficient data

73 (12)

18 (6)

55 (17)

  1. aPercentages for non-missing categories calculated amongst cases with valid responses